Intralesional mRNA 2752

Phase 1RNA therapy

LLaura Esserman

Intralesional mRNA 2752 is one of 9 biologic programs targeting Ductal Carcinoma in Situ. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ductal Carcinoma in SituActive, not recruiting

Ductal Carcinoma in SituPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Ductal Carcinoma in Situ

#DrugCompanyPhaseTrials

Orserdu

SStemline Therapeutics, Inc.

Phase 2

1 2

Keytruda

Merck & Co.

Phase 1

1 3

Z-Endoxifen

AAtossa Therapeutics, Inc.

Phase 2

1 4

Aromatase Inhibitor

Pfizer

Phase 1

1 5

Hiltonol

PPCI Biotech AS

Phase 1

1 6

CAN1012

CCanwell Biotech Limited

Phase 1

1 7

Pegylated IFN-Alpha 2b

GGynecologic Oncology Group

Preclinical

1 8

Intralesional mRNA 2752

LLaura Esserman

Phase 1

1 9

Herceptin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ductal Carcinoma in Situ1 trial

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Active, not recruiting·LLaura Esserman·Phase 1·NCT02872025·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intralesional mRNA 2752. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intralesional mRNA 2752 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intralesional mRNA 2752. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laura Esserman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: LLaura Esserman

Intralesional mRNA 2752

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ductal Carcinoma in Situ1 trial

References

Drug Info

Quick Facts

Related News